Abstract
We have evaluated the efficacy of interferon-α (IFN-α) plus zinc therapy in hepatitis C patients with genotype 1b, poor responders for IFN alone. Ten patients were injected with 10 MU of IFN-α every day for 4 wk, followed by three times a week for 20 wk (control group). Nine patients took 300 mg of zinc sulfate a day orally during IFN-α therapy (zinc sulfate group), and 15 patients took IFN-α and 150 mg of polaprezinc (polaprezinc group).
On the d 8 of IFN therapy, circadian zinc levels in serum elevated significantly in the polaprezinc group compared to the zinc sulfate group or control group. Serum ALT levels normalized in 73.3% of the polaprezinc group, 55.6% of the zinc sulfate group, and 40.0% of the control group at 6 mo after the end of IFN therapy. Sustained eradication for the hepatitis C virus RNA judged at the end of the 6-mo follow-up period was higher in the polaprezinc group than in the zinc sulfate group (53.3% vs 11.1%, p<0.05) or the control group (20.0%). No clinical side effects of zinc were observed at the dose used. The data suggest that polaprezinc is expected to increase the therapeutic response of IFN-α for chronic hepatitis C with genotype 1b.
Similar content being viewed by others
References
G. L. Davis, L. A. Balart, E. R. Schiff, K. Lindsay, H. C. Bodenheimer, Jr., R. P. Perrillo, et al., Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter, randomized, controlled trial, N. Engl. J. Med. 321, 1501–1506 (1989).
A. M. Di Bisceglie, P. Martin, C. Kassianides, M. Lisker-Melman, L. Murray, J. Waggoner, et al., Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial, N. Engl. J. Med. 321, 1506–1510 (1989).
M. Shindo, A. Di Bisceglie, and J. Hoofnagel, Long term follow-up of patients with chronic hepatitis C treated with alfa-interferon, Hepatology 45, 1013–1016 (1992).
M. L. Shiffman, C. M. Hofmann, V. A. Luketic, A. J. Sanyal, M. J. Contos, and A. S. Mills, Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose, Hepatology 24, 21–26 (1996).
K. L. Lindsay, G. L. Davis, E. R. Shiff, H. C. Bodenheimer, L. A. Balart, J. L. Dienstag, et al., Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial, Hepatology 24, 1034–1040 (1996).
J. Y. Lau, G. L. Davis, J. Kniffen, K. P. Qian, M. S. Urdea, C. S. Chan, et al., Significance of serum hepatitis C virus RNA levels in chronic hepatitis, Lancet 341, 1501–1504 (1993).
N. N. Zein and D. H. Persing, Hepatitis C genotypes: current trends and future implications, Mayo. Clin. Proc. 71, 458–462 (1993).
G. Rasi, D. DiVirgilio, M. G. Mutchnick, F. Colella, P. Sinibaldi-Vallebona, P. Piermarchi, et al., Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C, Gut 39, 679–683 (1996).
O. Reichard, R. Schvarcz, and O. Weiland, Therapy of hepatitis C: alpha interferon and ribavirin, Hepatology 26(Suppl. 1), 108S-111S (1997).
F. Farinati, R. Cardin, N. De Maria, G. Della Libera, C. Marafin, E. Lecis, et al., Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis, J. Hepatol. 22, 449–456 (1995).
J. K. Olynyk, K. R. Reddy, A. M. Di Bisceglie, L. J. Jeffers, T. I. Parker, J. L. Radick, et al., Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C, Gastroenterology 108, 1104–1109 (1995).
A. Piperno, M. Sampietro, R. D’Alba, L. Roffi, S. Fargion, S. Parma, et al., Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C, Liver 16, 248–254 (1996).
O. Beloqui, J. Prieto, M. Suarez, B. Gil, C. H. Qian, N. Garcia, et al., N-Acetyl cysteine enhances the response to interferon-αlfa in chronic hepatitis C: a pilot study, J. Interferon Res. 13, 279–282 (1993).
R. J. Cousins, Absorption, transport and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin, Physiol. Rev. 65, 238–309 (1985).
P. M. Hanna, M. B. Kadiiska, S. J. Jordan, and R. P. Mason, Role of metallothionein in zinc and chromium mediated tolerance to carbon tetrachloride hepatotoxicity: evidence against a trichloromethyl radical scavenging mechanism, Chem. Res. Toxicol. 6, 711–717 (1993).
M. Sato, J. Yamaki, T. Oguro, T. Yoshida, N. Nomura, and K. Nakajima, Induction of metallothionein synthesis by interferon α/β in response to zinc in mice, Tohoku J. Exp. Med. 178, 241–250 (1996).
B. D. Korant and B. E. Butterworth, Inhibition by zinc of rhinovirus protein cleavage: interaction of zinc with capsid polypeptides, J. Virol. 18, 298–306 (1976).
Y. J. Gordon, Y. Asher, and Y. Becker, Irreversible inhibition of herpes simplex virus and procapsid synthesis by zinc ions, Antimicrob. Agents Chemother. 8, 377–380 (1975).
E. Katz and E. Margalith, Inhibition of vaccina virus maturation by zinc chloride, Antimicrob. Agents Chemother. 19, 213–217 (1981).
M. Ratka, M. Lackmann, C. Ueckermann, U. Karlins, and G. Koch, Poliovirus-associated protein kinase: destabilization of the virus capsid and stimulation of the phosphorylation reaction by Zn2+, J. Virol. 63, 3954–3960 (1989).
Z. Y. Zhang, I. M. Reardon, J. O. Hui, K. L. O’Connell, R. A. Poorman, A. G. Tomasselli, et al., Zinc inhibition of renin and the protease from human immunodeficiency virus type 1, Biochemistry 10, 8717–8721 (1991).
B. Yoffe, S. Pollack, E. Ben-Porath, O. Zinder, D. Barzilai, and H. Gershon, Natural killer cell activity in post-necrotic cirrhotic patients as related to hepatitis-B virus infection and plasma zinc levels, Immunol. Lett. 14, 15–19 (1986).
C. Driessen, K. Hirv, L. Rink, and H. Kirchner, Induction of cytokines by zinc ions in human peripheral mononuclear cells and separated monocytes, Lymphokine Cytokine Res. 13, 15–20 (1994).
D. E. Poswillo and B. Cohen, Inhibition of carcinogenesis by dietary zinc, Nature 231, 447–448 (1971).
T. Nagamine, H. Takagi, Y. Hashimoto, H. Takayama, R. Shimoda, N. Nomura, et al., The possible role of zinc and metallothionein in the liver on the therapeutic effect of interferon-αlpha to hepatitis C patients, Biol. Trace Element Res. 58, 65–76 (1997).
H. Sano, S. Furuta, S. Totama, M. Miwa, Y. Ikeda, M. Suzuki, et al., Study on the metabolic fate of catena-(S)-[μ[N a-(3-aminopropionyl) histidinate(2-)-N 1,N 2,O:N τ]-zinc], Drug Res. 41(II), 965–975 (1991).
A. Miyoshi, H. Matsuo, G. Miwa, and M. Nakajima, Clinical evaluation of Z-103 in the treatment of gastric ulcer, Jpn. Pharmacol. Ther. 20, 181–197 (1992).
T. Yoshikawa, Y. Naito, T. Tanigawa, T. Yoneta, and M. Kondo, The antioxidant properties of a novel zinc-carnosine chelate compound, N-(3-aminopropionyl)-l-histidinate zinc, Biochem. Biophys. Acta 115, 15–22 (1991).
H. Okamoto, Y. Sugiyama, S. Okada, K. Kurai, Y. Akahane, Y. Sugai, et al., Detection of hepatitis C virus RNA typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources, J. Gen. Virol. 73, 673–679 (1992).
S. Karacyclin, A. Arcasoy, and O. Uzunalimoglu, Zinc plasma levels after oral zinc tolerance test in non-alcoholic cirrhosis, Dig. Dis. Sci. 30, 329–333 (1985).
G. Fernandes, M. Nair, K. Onoe, T. Tanaka, R. Flyd, and R. A. Good, Impairment of cell-mediated immunity functions by dietary zinc deficiency in mice, Proc. Natl. Acad. Sci. USA 70, 457–461 (1979).
M. Dardenne, J. M. Pleau, B. Nabarra, P. Lefrancier, D. M. Derrien, J. Choay, et al., Contribution of zinc and other metals to the biological activity of the serum thymic factor, Proc. Natl. Acad. Sci. USA 79, 5370–5373 (1982).
R. Kohen, Y. Yamamoto, K. C. Cundy, and B. N. Ames, Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain, Proc. Natl. Acad. Sci. USA 85, 3175–3179 (1988).
O. I. Arouma, M. J. Laughton, and B. Halliwell, Carnosine, homocarnosine and anserine: could they act as antioxidants in vivo? Biochem. J. 264, 863–869 (1989).
G. J. Fosmire, Zinc toxicity, Am. J. Clin. Nutr. 51, 225–227 (1990).
H. H. Sandstead, Requirements and toxicity of essential trace elements, illustrated by zinc and copper, Am. J. Clin. Nutr. 61, 621S-624S (1995).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nagamine, T., Takagi, H., Takayama, H. et al. Preliminary study of combination therapy with interferon-α and zinc in chronic hepatitis C patients with genotype 1b. Biol Trace Elem Res 75, 53–63 (2000). https://doi.org/10.1385/BTER:75:1-3:53
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/BTER:75:1-3:53